血清前列腺特异性抗原对前列腺良恶性肿瘤诊断的临床应用  

The application of prostate specific antigen in differential diagnosis of benign and malignant prostatic tumors

作　　者：胡海强[1] 朱雪萍[1] 宋捷[1] 潘慧娟[1] 张玉娜[1] 

机构地区：[1]上海市普陀区人民医院核医学科,200060

出　　处：《国际检验医学杂志》2017年第1期24-26,共3页International Journal of Laboratory Medicine

基　　金：上海市普陀区科委普陀区卫生系统自主创新科研资助项目(PTKW10-C01)

摘　　要：目的研究血清前列腺特异性抗原(tPSA)、复合前列腺特异性抗原(cPSA)及cPSA/tPSA比值(C/T)在前列腺增生(BPH)和前列腺癌(PCa)鉴别诊断中的应用。方法收集2009年5月至2015年12月该院门诊和住院患者血清共184例,其中BPH组患者80例,PCa组患者36例,其他疾病组患者68例。化学发光法检测tPSA、cPSA浓度,计算C/T值,比较3组的tPSA、cPSA浓度和C/T值。结果 PCa组血清tPSA、cPSA浓度及C/T值均高于其他疾病组和BPH组,且差异具有统计学意义(P<0.01);而BPH组和其他疾病组的C/T值差异无统计学意义(P>0.05);PCa组的tPSA和cPSA浓度相关性好,回归方程为cPSA=0.708×tPSA+0.219,且相关系数(r=0.956)高于BPH组的tPSA和cPSA浓度相关系数(r=0.651);血清tPSA浓度在4.0~10.0ng/mL灰区内各组间血清tPSA、cPSA浓度和C/T值差异无统计学意义(P>0.05)。结论联合检测血清tPSA、cPSA浓度并计算C/T值,在鉴别诊断前列腺良恶性肿瘤中具有重要意义。Objective To investigate serum total prostate special antigen（tPSA）,complexed prostate special antigen（cPSA）and cPSA/tPSA ratio（C/T）in the differential diagnosis of benign prostate hyperplasia（BPH）and prostate cancer（PCa）.Methods A total of 184 serum samples from hospital outpatient and inpatient were collected from May 2009 to December 2015,and which were divided into three groups including other diseases 68 patients,benign prostate hyperplasia（BPH group）80patients,prostate cancer（PCa group）36 patients.Chemiluminescence immunoassay was used to detect the concentration of tPSA and cPSA,and the C/T ratio were calculated in the study.Results The tPSA,cPSA levels and C/T ratio were significant different from patients with PCa,BPH and other diseases group（P〈0.01）.Compared with BPH group（r=0.651）,the tPSA and cPSA levels have a higher relativity in PCa group（cPSA=0.708×tPSA＋0.219,r=0.956）.While when tPSA level ranges 4.0-10.0ng/mL）,no significant difference of tPSA,cPSA levels and C/T ratio were found in these 3 groups（P〉0.05）.Conclusion Combined detection of serum tPSA,cPSA and C/T,making importance in the differential diagnosis of BPH and PCa.

关 键 词：前列腺特异性抗原 复合前列腺特异性抗原 前列腺增生 前列腺癌 

分 类 号：R737.25[医药卫生—肿瘤]